跳至主要内容
临床试验/NCT01675557
NCT01675557已完成4 期

Pharmacokinetic Comparison of Vitamin's D2 and D3 in Stage 5 Chronic Kidney

Creighton University2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2012年9月最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
30
试验地点
2
主要终点
25(OH)D

研究概览

简要总结

The purpose of this study is to compare the pharmacokinetic 25(OH)D and 1,25(OH)2D responses to a single oral dose of vitamin D2 or vitamin D3 in a group of Stage 5-Chronic Kidney Disease subjects requiring chronic hemodialysis.

详细描述

This is a randomized, single blind, controlled study. Subjects will be randomly assigned to receive 1) placebo capsules (control group); 2) capsules with ergocalciferol (the vitamin D2 group); or 3) capsules with cholecalciferol (the vitamin D3 group).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
20 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 30 men and women, ages 20-65, BMI 18-30, requiring chronic hemodialysis

排除标准

  • They will habitually consume less than 16 oz of milk per day and get less than 10 hours of sun exposure per week. We will exclude those with granulomatous conditions, cirrhotic liver disease, and those taking anticonvulsants, barbiturates, or steroids in any form or any investigational drugs within 4 weeks. We will exclude those with pregnancy or planned pregnancy, hypercalcemia (>10.4 mg/dl) previously recorded, chronic GI disease which would interfere with absorption, any allergy to vitamin D3, or chronic vitamin D intake >1,000 IU daily. Subjects will continue to take a calcitriol analogue and phosphorus binder as prescribed by their nephrologist. Calcitriol analogues are to be documented and remain constant throughout study.

结局指标

主要结局

25(OH)D

时间窗: 16 weeks

25(OH)D levels will be drawn at intervals over 16 weeks.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验